Save up to 90% on Abiraterone Acetate with Coupons, Discount Cards & Patient Assistance Programs

Abiraterone Acetate is available as 250 mg and 500 mg oral tablet.

Abiraterone Acetate is a CYP17 inhibitor indicated in combination with prednisone for the treatment of patients with:

• metastatic castration-resistant prostate cancer (CRPC)
• metastatic high-risk castration-sensitive prostate cancer (CSPC)

Abiraterone Acetate works by interrupting the androgen-making process at an important step. It inhibits androgen at 3 sources—the testes, the adrenal glands, AND the tumor itself.

Abiraterone Acetate is typically taken for:

Metastatic castration-resistant prostate cancer:

• Abiraterone Acetate 1,000 mg orally once daily with prednisone 5 mg orally twice daily

Metastatic castration-sensitive prostate cancer:

• Abiraterone Acetate 1,000 mg orally once daily with prednisone 5 mg orally once daily
• Patients receiving Abiraterone Acetate should also receive a gonadotropin-releasing
• hormone (GnRH) analog concurrently or should have had bilateral orchiectomy
• Abiraterone Acetate tablets must be taken as a single dose once daily on an empty stomach
• Do not eat food 2 hours before and 1 hour after taking Abiraterone Acetate. The tablets must be swallowed whole with water. Do not crush or chew tablets

Abiraterone Acetate is a safe and effective treatment when used for FDA licensed indications. However, like all medications, they may give you unwanted side effects. You should always discuss potential side effects with your physician to ensure the medication is suitable and right for you.

Common side effects of Abiraterone Acetate:

• Fatigue
• Arthralgia
• Hypertension
• Nausea
• Edema
• Hypokalemia
• Hot flush
• Diarrhea
• Vomiting
• Upper respiratory infection
• Cough
• Headache

Serious side effects are rare with Abiraterone Acetate. Some examples include:

• High blood pressure (hypertension), low blood potassium levels (hypokalemia), fluid retention (edema), and irregular heartbeats
• Adrenal problems
• Severe liver problems
• Liver problems.
• Low blood sugar
• Increased risk of bone fracture and death

The following medications may interact with Abiraterone Acetate:

• CYP3A4 Inducers: Avoid concomitant strong CYP3A4 inducers during Abiraterone Acetate treatment. If a strong CYP3A4 inducer must be co-administered, increase the Abiraterone Acetate dosing frequency CYP2D6 Substrates: Avoid co-administration of Abiraterone Acetate with CYP2D6 substrates that have a narrow therapeutic index. If an alternative treatment cannot be used, exercise caution and consider a dose reduction of the concomitant CYP2D6 substrate

Various FDA-approved generic manufacturers

The safety and efficacy of Abiraterone Acetate have not been established in females. Based on findings from animal studies and the mechanism of action, Abiraterone Acetate can cause fetal harm and potential loss of pregnancy.

• Zytiga